Comparing the current results to its competitors, Pacific Biosciences Of California Inc reported Revenue decrease in the 2 quarter 2026 year on year by -1.71 %, despite the revenue increase by the most of its competitors of 10.62 %, recorded in the same quarter.
Pacific Biosciences Of California Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.07 %
November 5, 2025
The landscape of genomic research is evolving rapidly, particularly with regard to the need for precision and accuracy in identifying clinically relevant genetic variants. A recent multi-center study has demonstrated the capabilities of Pacific Biosciences’ (PacBio) HiFi genome sequencing technology, establishing its potential value in both research and clinical applications. This article synthesizes the findings from this study with the company s recent financial performance metrics, emphasizing the implications for clinical genomics. HiFi Genome Technology: Key Findings from the Multi-Center StudyIn a groundbreaking study published by the HiFi Solves Consortium, researchers evaluated the efficacy of Pac...
October 11, 2024
In a groundbreaking alliance poised to redefine the landscape of cancer genomics, PacBio has joined forces with Singapore’s National Precision Medicine (NPM) program. This strategic partnership aims to harness the full potential of PacBio’s state-of-the-art HiFi sequencing technology, a sophisticated solution designed to deliver unparalleled insights into genetic diversity, disease mechanisms, and clinical diagnoses. The collaboration promises to accelerate breakthroughs in cancer research across Asia, specifically tailored to address the unique genetic landscape of Singapore s multi-ethnic population.The importance of this collaboration cannot be overstated, especially considering the burgeoning field o...
October 1, 2024
In a remarkable stride for the field of genomics, PacBio, A STAR, and Macrogen have collaborated to unveil a cutting-edge lab in Singapore, poised to revolutionize access to advanced genomic technologies in Southeast Asia. The initiative aims to leverage Pacific Biosciences’ state-of-the-art HiFi sequencing technology, making highly accurate long-read sequencing and multi-omics solutions more accessible to researchers and healthcare professionals across the region.As the world increasingly pivots towards personalized medicine and genomic research, this innovative lab represents a beacon of progress within a field often constrained by technological limitations. By utilizing PacBio’s superior HiFi sequenci...
September 11, 2024
In a groundbreaking announcement that promises to reshape the landscape of reproductive health, Pacific Biosciences of California Inc. (PacBio) unveiled the HiFi Solves Sub-fertility Consortium this month. This innovative collaboration aims to utilize the power of HiFi sequencing to advance diagnostics and treatment options for subfertility and recurrent pregnancy loss, addressing a pressing issue faced by many couples across the Asia Pacific region.Subfertility, defined as the inability to conceive after a year of trying, affects millions of couples worldwide. In Asia Pacific alone, the statistics are staggering one in six couples experiences difficulty in conceiving. This stark reality has led to an urgent...
August 5, 2024
Advancing Precision Medicine in Southeast Asia: Singapore s National Precision Medicine Programme Teams Up with PacBioIn a significant development for the field of genomics and precision medicine, Singapore s National Precision Medicine (NPM) programme has announced a strategic partnership with Pacific Biosciences of California, Inc. (PacBio) to implement state-of-the-art HiFi sequencing technology across Singapore and, by extension, Southeast Asia. This collaboration aims to deepen our understanding of genetic diversity, disease mechanisms, and clinical diagnoses within Singapore s diverse multi-ethnic population. The Significance of High-Fidelity SequencingThe introduction of PacBio s HiFi sequencing tech...
July 23, 2024
Unleashing the Power of Long-Read Sequencing: Novogene Revolutionizes Research and Opens New Doors for Precision MedicineIn a groundbreaking move that promises to propel cancer, rare disease, and environmental research to new heights, Novogene, a global leader in genomic services and solutions, has announced the launch of its state-of-the-art laboratory in Munich. Equipped with cutting-edge PacBio sequencing technology, the facility aims to provide highly accurate long-read sequencing data to support its extensive network of partners, which includes renowned research institutions around the world. This momentous development heralds a new era in genomic research, offering unprecedented opportunities for unrav...
Publicly Traded Peers of Pacific Biosciences Of California Inc
Illumina Inc Share Performance
+7.38%
30 Days
Illumina Inc
Profile
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Bionano Genomics Inc is a biotechnology company specializing in the development and commercialization of genomic analysis tools. Their business model revolves around offering proprietary genome imaging systems that provide high-resolution maps of DNA for researchers and clinicians to study genetic variations and diseases more effectively.
Nautilus Biotechnology Inc's business model focuses on using advanced genomics and proteomics technologies to analyze and understand the human proteome.
Sources:
Pacific Biosciences Of California Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pacific Biosciences Of California Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
